LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) and Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.
Insider & Institutional Ownership
54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 6.9% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares LENZ Therapeutics and Abeona Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENZ Therapeutics | $19.09 million | 13.79 | -$49.77 million | ($2.81) | -2.99 |
| Abeona Therapeutics | $5.82 million | 42.05 | $71.18 million | $1.03 | 4.17 |
Abeona Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares LENZ Therapeutics and Abeona Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENZ Therapeutics | N/A | -37.47% | -35.13% |
| Abeona Therapeutics | N/A | -60.65% | -40.78% |
Analyst Ratings
This is a summary of recent ratings and price targets for LENZ Therapeutics and Abeona Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENZ Therapeutics | 1 | 1 | 6 | 0 | 2.63 |
| Abeona Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
LENZ Therapeutics presently has a consensus target price of $45.60, suggesting a potential upside of 442.86%. Abeona Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 342.89%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe LENZ Therapeutics is more favorable than Abeona Therapeutics.
Volatility and Risk
LENZ Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
About Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
